IPO Issue Details
Issue Price / Price Band₹448 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size33 Shares per Lot
Total Issue Size1,27,23,214 shares (aggregating up to ₹570.00 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenThu, 21 Dec 2023
Subscription CloseTue, 26 Dec 2023
Anchor AllotmentWed, 20 Dec 2023
Basis of AllotmentWed, 27 Dec 2023
Initiation of RefundsThu, 28 Dec 2023
Credit of Shares to DematThu, 28 Dec 2023
Listing DateFri, 29 Dec 2023
UPI Mandate Deadline2023-12-26
Application & Investment Details
Retail — Min (1 Lots)₹14,784 — 33 shares
Retail — Max (13 Lots)₹192,192 (13 Lots)
HNI — Min (14 Lots)₹2,06,976 — 462 shares
EPS (Pre-IPO)₹14.16
P/E Ratio (Pre-IPO)31.64x
P/E Ratio (Post-IPO)36.42x
Post-IPO Promoter Holding5,72,24,929 shares
Fresh Issue Shares71,42,857 shares (aggregating up to ₹320.00 Cr)
Offer for Sale Shares55,80,357 shares of ₹10 (aggregating up to ₹250.00 Cr)
About Innova Captab Ltd.
Incorporated in January 2005, Innova Captab Limited is a pharmaceutical company operating in three business segments. Firstly, it provides contract development and manufacturing services to Indian pharmaceutical companies. Secondly, the company has a domestic business dealing in branded generics. And thirdly, the company has an international business that deals in branded generics.The company's product portfolio includes tablets, capsules, dry syrups, dry powder injections, ointments and liquid medicines.In the financial year 2023 and the three months ended June 30, 2023, the company produced and sold more than 600 different types of generics. These products were distributed under the company's own brands in the Indian market through a network of approximately 5,000 distributors and stockists and over 150,000 retail pharmacies. In addition, Innova Capitab exported its branded generic products to 20 and 16 countries in FY2023 and the three months ended June 30, 2023, respectively.As of October 31, 2023, the company employed a team of 29 scientists and engineers in its research and development laboratory. The company's manufacturing facility is located in Buddi, HaryanaThe company's customer base includes Cipla, Glenmark Pharmaceuticals, Wockhardt, Corona Remedies, Emcure Pharmaceuticals, Lupin, Medley Pharmaceuticals, Eris Healthcare, Zuventus Healthcare, Ajanta Pharma, Mankind Pharma, and others.As of October 31, 2023, the company has 200 active product registrations and 20 registrations pending renewal with international authorities. In addition, 218 new registration applications are being processed with international authorities.
Objects of the Issue
Innova Captab Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
Repayment and / or prepayment in part or in full, of certain outstanding loans of the Company;
2
Investment in the Subsidiary, UML, for repayment and / or prepayment in part or full of outstanding loans availed by UML;
3
Funding the working capital requirements; and
4
General corporate purposes
Shareholding & Lock-in
Pre-IPO Promoter Holding
Not Available
Post-IPO Promoter Holding
5,72,24,929 shares
Lock-in Period (30%)January 26, 2024
Lock-in Period (50%)March 26, 2024